Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein
AssigneesNational Cancer Center, Rin Institute Inc.
InventorsYasuhiro Matsumura, Shingo Hanaoka, Shinji Saijo
Life of this patent
Estimating the term…
Abstract
The present invention provides a fusion protein suitable for dissolving a fibrin clot and a pharmaceutical composition containing the fusion protein. According to the present invention, there is provided a fusion protein of an antibody that binds to insoluble fibrin or an antigen-binding fragment thereof and a prourokinase mutant, in which amino acid sequence of a plasmin in a kringle domain is modified so as to be less cleavable with a plasmin, and a pharmaceutical composition containing the fusion protein.
Claims9
A fusion protein comprising an antibody that binds to insoluble fibrin or an antigen-binding fragment thereof and a prourokinase mutant comprising a catalytic domain of prourokinase, wherein the antibody or the antigen-binding fragment thereof and the prourokinase mutant are linked directly or via a linker to each other, wherein the insoluble fibrin antibody or the antigen-binding fragment thereof comprises:
- a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:11, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:12, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:13;
- and
- a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:14, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:15, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:16.
Dependencies are inferred from the claim text.